GuidelineChest2026
Critical Gaps in the Scientific Basis for Electronic Cigarette Regulation: An American College of Chest Physicians Research Statement.
Guideline in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe 2009 Family Smoking Prevention and Tobacco Control Act granted the US Food and Drug Administration regulatory authority over tobacco products, extended to include electronic cigarettes (ECs) in 2016. Regulatory science informs potential market restrictions based on the population health standard. The American College of Chest Physicians (CHEST) Tobacco/Vaping Work Group is charged with prioritizing tobacco-related advocacy. To identify critical gaps in the science guiding EC regulation, we undertook a systematic exploration of existing evidence to develop future research recommendations.
methodsFifteen CHEST Tobacco/Vaping Work Group members with relevant expertise in tobacco science, health policy, and methodology prioritized 12 candidate research areas and selected the 4 highest-ranked questions for review: accessibility limitations, nicotine delivery limits, non-cardiac/non-malignant risks, and flavorant impact on airway biology. A comprehensive literature search was conducted, and relevant studies were reviewed to develop recommendations through group consensus. KEY FINDINGS AND RECOMMENDATIONS: While age-appropriate restrictions reduce uptake, alternative access channels limit their impact, necessitating pragmatic trials of various restrictions and enforcement methods. Limiting nicotine delivery may lead to compensatory behaviors and increased toxicant exposure, requiring pharmacokinetic assessments that account for substantive variations in user behavior. Associations between EC use and respiratory symptoms, mood disorders, attentional disturbances, and poor academic performance underscore the need for epidemiologic and mechanistic research into non-cardiac/non-malignant health risks. There is strong evidence that flavorant aerosols induce cytotoxicity in mammalian cells; however, their specific effects on humans remain insufficiently studied to inform product regulation.
conclusionsGaps in EC regulatory science hinder effective policy development. The panel recommends a focused research agenda addressing pragmatic trials of access restrictions, detailed evaluation of nicotine delivery limits, investigation of non-cardiac/non-malignant risks, and quantification of aerosol toxicity, with attention to diverse real-world use patterns to better inform regulation and protect public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.